The forced swim test has poor accuracy for identifying novel antidepressants.

Emily R Trunnell, Constança Carvalho

Drug discovery today 2021 Dec

filter terms:

Despite the prevalence of treatment-resistant depression, many pharmaceutical companies have abandoned the development of new antidepressants. Experts have attributed this, in part, to the low quality of preclinical tests available in this field, often citing over-reliance on animal behavioral screens, such as the forced swim test (FST). This retrospective review assessed whether compounds tested in the FST by major pharmaceutical companies were shown to have antidepressant effects in humans. Of 109 compounds identified, only 28% had been explored for antidepressant effects in humans. Of these, there were only three for which the FST appeared to positively predict antidepressant efficacy, but none are currently approved to treat any type of depression. With such poor accuracy for identifying novel antidepressants, the FST might not be a useful screening tool for this purpose. Copyright © 2021 Elsevier Ltd. All rights reserved.

Citation

Emily R Trunnell, Constança Carvalho. The forced swim test has poor accuracy for identifying novel antidepressants. Drug discovery today. 2021 Dec;26(12):2898-2904